Free Newsletter
Pfizer narrows post-merger R&D focus
Free newsletter via e-mail
Tools
Pfizer is whacking about 100 drug development programs out of a pipeline swollen by its merger with Wyeth. Reuters reports that the bulk of the remaining 500 programs focus on six key areas: Oncology, pain, inflammation, Alzheimer's disease, psychoses and diabetes. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: